ZYME · Zymeworks

The thesis

Zymeworks shares have a modest edge over the S&P 500 because the company raised its 2026 revenue guidance to $337 million to $351 million on 9 November 2026 and Ziihera royalties grew for a second quarter. Two events settle it: antitrust clearance of the Roche licence, which the company expects in the fourth quarter of 2026, and Jazz Pharmaceuticals' next report of Ziihera sales.

The third-quarter report on 9 November 2026 delivered on both counts that mattered. Ziihera royalty revenue from Jazz and BeOne Medicines was $2.3 million, up from $1.8 million in the second quarter, per the company's 8-K. Adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) guidance rose to $176 million to $190 million from $114 million to $128 million.

The raised guidance rests on one condition. The company states it is subject to the end of the Hart-Scott-Rodino antitrust waiting period for the Roche ZW209 collaboration, which brings a $55 million non-refundable upfront. A slip past year-end would put the new range at risk.

The price reflects scepticism about how much of the quarter repeats. Third-quarter revenue of $256.5 million included a $250.0 million Jazz milestone for the 25 August 2026 first-line approval. The shares closed at $29.07 on 11 November 2026, below all four analyst targets raised on 10 November 2026 and 11 November 2026, the lowest of them Truist's $36.

Bullish and bearish views on Zymeworks Inc.

The bull case on Zymeworks Inc. (ZYME), in brief: guidance rose by a wide margin. The bear case: the headline quarter was one payment.

Bull case

• Guidance rose by a wide margin. The 9 November 2026 release lifted 2026 revenue guidance to $337 million to $351 million from $278 million to $292 million. Benzinga had put the consensus estimate at $302.672 million.
• Royalties are climbing with the launch. Royalty revenue was $2.3 million in the third quarter against $1.8 million in the second (company 8-Ks, 9 November 2026 and 6 August 2026). Jazz reported $20.6 million of third-quarter Ziihera sales on 2 November 2026, against $8.3 million a year earlier. The fourth quarter is the first full quarter after the first-line approval.
• First-line demand started strongly. Jazz's 2 November 2026 release reports about 40% more demand vials per selling day in the first full month after approval. New ordering accounts tripled, 80% of them community-based.
• The quarter was profitable. Net income was $173.7 million and diluted earnings per share $2.28 in the third quarter, against a $2.18 estimate (Benzinga, 9 November 2026). Net interest expense fell to $4.2 million from $6.6 million in the second quarter.
• Pipeline earns outside money. Roche agreed on 22 October 2026 to pay $55 million upfront, $40 million at the start of a Phase 1b trial of ZW209 and up to $718 million in further milestones (Zymeworks 8-K). ZW191 showed a 64.5% confirmed objective response rate at 6.4 mg/kg in ovarian cancer at the European Society for Medical Oncology congress on 24 October 2026.
• Analysts raised targets after the report. Citigroup raised its target to $44 on 11 November 2026. HC Wainwright moved to $56, TD Cowen to $39 and Truist to $36 on 10 November 2026.

Bear case

• The headline quarter was one payment. Of $256.5 million of third-quarter revenue, $250.0 million was a single Jazz milestone (8-K, 9 November 2026). Quarters without a milestone have missed estimates before: second-quarter revenue was $4.590 million against an $18.011 million estimate (Benzinga, 6 August 2026).
• Cash fell sharply this year. Cash, cash equivalents and short-term securities were $100.5 million on 30 September 2026, against $228.8 million on 31 December 2025. The company spent $140.4 million on 5,737,790 of its own shares in the first nine months of 2026.
• Lenders sit ahead of shareholders. Total liabilities were $918.2 million on 30 September 2026, including a $250 million Royalty Pharma note backed by Ziihera royalties and a $350 million OMERS Life Sciences note backed by YUPELRI cash flows.
• Royalties remain small in dollars. The $2.3 million third-quarter royalty compares with $4.2 million of net interest expense in the same quarter (8-K, 9 November 2026).
• YUPELRI is barely growing. Viatris reported third-quarter U.S. YUPELRI net sales of $71.5 million, up 0.2% year on year, per the company's 9 November 2026 release.

Price setup

The shares closed at $29.07 on 11 November 2026, down from $31.46 a session earlier. The 52-week intraday high of $31.97 came on 10 November 2026, the session after the report, and the last close sits 9.1% below it. The 3-month change is 12.8% from the $25.76 close on 13 August 2026.

The 50-day moving average was $27.48 and the 200-day $25.48 on 11 November 2026, both under the price. The $28.73 close of 5 November 2026 is the nearest prior level. Lower down, the $25.75 close of 15 October 2026 and the company's $24.48 average buyback price for 2026 mark the zone where the gains since the Roche licence would be gone. The 52-week closing low is $18.50, set on 13 November 2025.

Catalysts ahead

• 17 November 2026: Jefferies healthcare conference fireside chat, London. Management's public setting after a report without a call, likely covering fourth-quarter royalty trends and the timing of Roche antitrust clearance.
• ~15 December 2026 (est.): Antitrust clearance for the Roche ZW209 licence (company expects Q4 2026). Clearance triggers the $55M upfront and satisfies the condition the raised $337M-$351M revenue guidance rests on; no date has been announced.
• 13 December 2026: ZW1953 preclinical poster at the American Society of Hematology meeting. A first public look at an early programme; it adds pipeline detail but is unlikely to move royalty or guidance figures.
• 11 February 2027: Zymeworks R&D Day, New York. Shows the development plans and data for ZW191, ZW209 and the rest of the pipeline that the Roche deal priced.
• ~25 February 2027 (est.): Jazz Pharmaceuticals Q4 2026 results with Ziihera sales. The first full quarter of first-line sales; a rise above Q3's $20.6M supports royalty growth, a fall below it breaks the case.

What would change the view

A weekly close below $25.00, under the 15 October 2026 close of $25.75 and near the company's $24.48 average 2026 buyback price, which would erase the gains since the Roche licence. Jazz reporting fourth-quarter 2026 Ziihera sales below the third quarter's $20.6 million would also show the case failing.

The risks this note tracks, each with what would confirm it:

• First-line uptake fades after a strong first month, leaving Ziihera royalties small relative to debt service. Confirmed by: a Q4 2026 Ziihera royalty at or below Q3's $2.3M, or Jazz reporting a sequential fall in Ziihera sales.
• Roche antitrust clearance slips, undoing the condition behind the raised 2026 guidance. Confirmed by: the HSR waiting period not ending by 31 December 2026, or the company resetting the $337M-$351M revenue range.
• Cash thins as buybacks and operating costs run ahead of milestone receipts. Confirmed by: year-end 2026 cash, equivalents and short-term securities below the $100.5M reported for 30 September 2026.
• Debt service on two non-recourse notes absorbs a growing share of royalty and profit-share cash. Confirmed by: quarterly net interest expense above the $6.6M recorded in Q2 2026, or filed terms showing a larger lender share of cash flows.
• ZW191 or ZW209 disappoint as trials grow beyond small Phase 1 groups. Confirmed by: weaker response rates at the 11 February 2027 R&D Day, a clinical hold, or a delay to the ZW209 Phase 1 start the company expects in 2026.

What it trades with

The shares move most on Jazz's Ziihera disclosures, so Jazz's quarterly reports act as the early read on Zymeworks' royalty line. Roche news on ZW209, the antitrust clearance and Theravance-related YUPELRI and TRELEGY updates are the other company-specific drivers. Beyond those, the stock tends to trade with small and mid-cap biotech sentiment.